Sections
| Title | Starting Page | Number of Pages |
|---|
| 1 Table of Contents | 2 | 4 |
| 1.1 List of Tables | 4 | 1 |
| 1.2 List of Figures | 5 | 1 |
| 2 Introduction | 6 | 1 |
| 2.1 Viscosupplementation Overview | 6 | 1 |
| 3 Products under Development | 7 | 6 |
| 3.1 Viscosupplementation - Pipeline Products by Stage of Development | 7 | 1 |
| 3.2 Viscosupplementation - Pipeline Products by Segment | 8 | 1 |
| 3.3 Viscosupplementation - Pipeline Products by Territory | 9 | 1 |
| 3.4 Viscosupplementation - Pipeline Products by Regulatory Path | 10 | 1 |
| 3.5 Viscosupplementation - Pipeline Products by Estimated Approval Date | 11 | 1 |
| 3.6 Viscosupplementation - Ongoing Clinical Trials | 12 | 1 |
| 4 Viscosupplementation - Pipeline Products under Development by Companies | 13 | 2 |
| 4.1 Viscosupplementation Companies - Pipeline Products by Stage of Development | 13 | 1 |
| 4.2 Viscosupplementation - Pipeline Products by Stage of Development | 14 | 1 |
| 5 Viscosupplementation Companies and Product Overview | 15 | 29 |
| 5.1 Anika Therapeutics, Inc. Company Overview | 15 | 1 |
| 5.1.1 Anika Therapeutics, Inc. Pipeline Products &Ongoing Clinical Trials Overview | 15 | 5 |
| 5.2 BioPolymer GmbH &Co. KG Company Overview | 20 | 1 |
| 5.2.1 BioPolymer GmbH &Co. KG Pipeline Products &Ongoing Clinical Trials Overview | 20 | 3 |
| 5.3 Bioventus LLC Company Overview | 23 | 1 |
| 5.3.1 Bioventus LLC Pipeline Products &Ongoing Clinical Trials Overview | 23 | 1 |
| 5.4 Carbylan Therapeutics, Inc. Company Overview | 24 | 1 |
| 5.4.1 Carbylan Therapeutics, Inc. Pipeline Products &Ongoing Clinical Trials Overview | 24 | 4 |
| 5.5 Carticept Medical, Inc. Company Overview | 28 | 1 |
| 5.5.1 Carticept Medical, Inc. Pipeline Products &Ongoing Clinical Trials Overview | 28 | 1 |
| 5.6 Chi2Gel Ltd. Company Overview | 29 | 1 |
| 5.6.1 Chi2Gel Ltd. Pipeline Products &Ongoing Clinical Trials Overview | 29 | 1 |
| 5.7 Cocoon Biotech, Inc. Company Overview | 30 | 1 |
| 5.7.1 Cocoon Biotech, Inc. Pipeline Products &Ongoing Clinical Trials Overview | 30 | 1 |
| 5.8 DePuy Synthes, Inc. Company Overview | 31 | 1 |
| 5.8.1 DePuy Synthes, Inc. Pipeline Products &Ongoing Clinical Trials Overview | 31 | 1 |
| 5.9 Flex Biomedical, Inc. Company Overview | 32 | 1 |
| 5.9.1 Flex Biomedical, Inc. Pipeline Products &Ongoing Clinical Trials Overview | 32 | 1 |
| 5.10 Hanmi Pharmaceuticals, Co. Ltd. Company Overview | 33 | 1 |
| 5.10.1 Hanmi Pharmaceuticals, Co. Ltd. Pipeline Products &Ongoing Clinical Trials Overview | 33 | 4 |
| 5.11 Maxigen Biotech Inc. Company Overview | 37 | 1 |
| 5.11.1 Maxigen Biotech Inc. Pipeline Products &Ongoing Clinical Trials Overview | 37 | 2 |
| 5.12 Moebius Medical Ltd. Company Overview | 39 | 1 |
| 5.12.1 Moebius Medical Ltd. Pipeline Products &Ongoing Clinical Trials Overview | 39 | 1 |
| 5.13 Shanghai Haohai Biological Technology Co., Ltd. Company Overview | 40 | 1 |
| 5.13.1 Shanghai Haohai Biological Technology Co., Ltd. Pipeline Products &Ongoing Clinical Trials Overview | 40 | 1 |
| 5.14 Spring Therapeutics Company Overview | 41 | 1 |
| 5.14.1 Spring Therapeutics Pipeline Products &Ongoing Clinical Trials Overview | 41 | 1 |
| 5.15 Synolyne Pharma Company Overview | 42 | 1 |
| 5.15.1 Synolyne Pharma Pipeline Products &Ongoing Clinical Trials Overview | 42 | 1 |
| 5.16 University of Kansas Company Overview | 43 | 1 |
| 5.16.1 University of Kansas Pipeline Products &Ongoing Clinical Trials Overview | 43 | 1 |
| 6 Viscosupplementation- Recent Developments | 44 | 17 |
| 6.1 Jul 28, 2016: Smith &Nephew Second Quarter Trading and First Half 2016 Results | 44 | 3 |
| 6.2 Jul 27, 2016: Anika Reports Second Quarter 2016 Financial Results | 47 | 1 |
| 6.3 Jul 19, 2016: Bioventus Withdraws IPO | 47 | 1 |
| 6.4 Jul 11, 2016: CFO to leave Smith &Nephew in early 2017 | 48 | 1 |
| 6.5 Jul 05, 2016: Fidia Presents New Data on Hymovis, a Breakthrough in Viscoelastic Technology, at the American Orthopaedic Society for Sports Medicine 2016 Annual Meeting | 48 | 1 |
| 6.6 Jul 01, 2016: Bioventus Extends Distribution Agreement for SUPARTZ FX | 49 | 1 |
| 6.7 Jun 24, 2016: Michael Minogue Named to Bioventus Board of Managers | 49 | 1 |
| 6.8 Jun 01, 2016: Anika Announces European Commercial Launch of CINGAL for the Treatment of Pain Associated with Osteoarthritis | 50 | 1 |
| 6.9 May 31, 2016: Fidia Announces US Commercial Availability of Hymovis, a Next-Generation Hyaluronan | 50 | 1 |
| 6.10 May 19, 2016: Pendopharm Announces Canadian Launch Of Cingal In Partnership With Anika Therapeutics | 51 | 1 |
| 6.11 Apr 27, 2016: Anika Reports First Quarter 2016 Financial Results | 51 | 1 |
| 6.12 Apr 04, 2016: Anika Appoints New Chief Medical Officer and Chief Operations Officer | 52 | 1 |
| 6.13 Mar 28, 2016: Anika Therapeutics Wins CE Mark Approval For Cingal For The Treatment Of Pain Associated With Osteoarthritis Of The Knee | 53 | 1 |
| 6.14 Mar 08, 2016: Peter Mitchell Named Chief Scientific Officer At Cocoon Biotech | 53 | 1 |
| 6.15 Feb 25, 2016: Fidia Introduces Hymovis, a Next-Generation Hyaluronan, at the AAOS Annual Meeting in Orlando | 54 | 1 |
| 6.16 Feb 24, 2016: Anika Therapeutics Delivers Strong Performance with Record Product Revenue for the Fourth Quarter and Full Year 2015 | 54 | 1 |
| 6.17 Jan 22, 2016: BONESUPPORT Announces Appointment Of Life Sciences Industry Veteran, Richard Davies, As New Chief Executive Officer | 55 | 1 |
| 6.18 Dec 09, 2015: Anika Therapeutics Announces Decision to Proceed with CINGAL Premarket Review Through FDA's Center for Drug Evaluation and Research | 56 | 1 |
| 6.19 Dec 01, 2015: Zimmer Biomet Announces Expanded FDA Safety Claim for Gel-One Cross-Linked Hyaluronate | 57 | 1 |
| 6.20 Nov 03, 2015: Anika Therapeutics Announces Health Canada Approval of CINGAL for the Treatment of Pain Associated with Osteoarthritis of the Knee | 57 | 1 |
| 6.21 Nov 02, 2015: Fidia Presents Hymovis, a New Generation Hyaluronan, at the ACR Annual Meeting in San Francisco | 57 | 1 |
| 6.22 Nov 02, 2015: Fidia Presents Hymovis, a New Generation Hyaluronan, at the ACR Annual Meeting in San Francisco | 58 | 1 |
| 6.23 Oct 29, 2015: Anika Appoints Richard Hague to Role of Chief Commercial Officer | 58 | 1 |
| 6.24 Oct 28, 2015: Anika Therapeutics Reports Robust Financial Performance and Continued Progress on Key Fronts in Third Quarter of 2015 | 59 | 2 |
| 7 Appendix | 61 | 4 |
| 7.1 Methodology | 61 | 2 |
| 7.2 About GlobalData | 63 | 1 |
| 7.3 Contact Us | 63 | 1 |
| 7.4 Disclaimer | 64 | 1 |
